Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Inhalation of a Free Combination of Tiotropium Once Daily 18 Mcg and Salmeterol Twice Daily 50 Mcg Versus a Fixed Combination of Fluticasone and Salmeterol Twice Daily (500/50 Mcg) on Static Lung Volumes and Exercise Tolerance in COPD Patients (a Randomised, Double-blind, Double Dummy, 16 (2 x 8) Weeks, Crossover Study).
Brief Summary: The primary objective of this study is to demonstrate that treatment with a free combination of tiotropium and salmeterol provides superior improvement in static lung volumes and exercise tolerance compared to a fixed combination of fluticasone and salmeterol in patients with COPD.

The secondary objective includes assessment of safety.


Options:
A: Intervention Type: DRUG; Name: Tiotropium plus Salmeterol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone/Salmeterol; Assigned to Arm(s): N/A
B: Arm Label: Umeclidinium/vilanterol Arm; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium/vilanterol, Drug: Placebo | Arm Label: Fluticasone propionate/salmeterol Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol, Drug: Placebo | Intervention Type: DRUG; Name: Umeclidinium/vilanterol; Assigned to Arm(s): Umeclidinium/vilanterol Arm | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol; Assigned to Arm(s): Fluticasone propionate/salmeterol Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fluticasone propionate/salmeterol Arm, Umeclidinium/vilanterol Arm
C: Arm Label: UMEC/ VI via NDPI + placebo ACCUHALER/DISKUS arm; Type: EXPERIMENTAL; Interventions: Drug: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, Drug: Placebo DISKUS | Arm Label: FSC via ACCUHALER/DISKUS + placebo NDPI arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS, Drug: Placebo NDPI | Intervention Type: DRUG; Name: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI; Assigned to Arm(s): UMEC/ VI via NDPI + placebo ACCUHALER/DISKUS arm | Intervention Type: DRUG; Name: FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS; Assigned to Arm(s): FSC via ACCUHALER/DISKUS + placebo NDPI arm | Intervention Type: DRUG; Name: Placebo DISKUS; Assigned to Arm(s): UMEC/ VI via NDPI + placebo ACCUHALER/DISKUS arm | Intervention Type: DRUG; Name: Placebo NDPI; Assigned to Arm(s): FSC via ACCUHALER/DISKUS + placebo NDPI arm
D: Arm Label: Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium bromide/Vilanterol, Drug: Placebo ACCUHALER/DISKUS | Arm Label: Fluticasone propionate/Salmeterol + placebo NDPI; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/Salmeterol, Drug: Placebo NDPI | Intervention Type: DRUG; Name: Umeclidinium bromide/Vilanterol; Assigned to Arm(s): Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS | Intervention Type: DRUG; Name: Placebo ACCUHALER/DISKUS; Assigned to Arm(s): Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS | Intervention Type: DRUG; Name: Fluticasone propionate/Salmeterol; Assigned to Arm(s): Fluticasone propionate/Salmeterol + placebo NDPI | Intervention Type: DRUG; Name: Placebo NDPI; Assigned to Arm(s): Fluticasone propionate/Salmeterol + placebo NDPI

Answer: A